ELTX Stock Forecast & Price Target

Elicio Therapeutics is a promising investment opportunity as its Phase 2 trial for ELI-002 7P has shown efficacy in specific patient groups and the company's AMP technology has potential for various cancer treatments. The drug daraxonrasib also shows promise in treating pancreatic cancer and could contribute to future revenue. However, risks could arise from the company's co-owned application with Cornell University, potentially affecting revenue generation.

Elicio Therapeutics is a clinical-stage biotechnology company developing off-the-shelf immunotherapies for the treatment of cancer. While the company's proprietary Amphiphile (AMP) technology has shown potential in pre-clinical studies, their clinical data for ELI-002 7P in mKRAS-positive pancreatic cancer has been underwhelming, with no dose-limiting toxicities or serious adverse events, but also no significant efficacy demonstrated. Additionally, the company's other vaccine targets, ELI-007 and ELI-008, are still preclinical and subject to funding, making it difficult to forecast their potential contribution to the company's pipeline. These factors, combined with the dispersed mutation landscape of their primary vaccine target, mutant p53, and the lack of a clear commercialization strategy, create a negative outlook for Elicio Therapeutics' stock.